Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Olsson, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Olsson, T.

Neurology, Vol 45, Issue 6 S11-S15, Copyright © 1995 by American Academy of Neurology

VIEWS & REVIEWS

Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis

T Olsson
Department of Medicine, Karolinska Hospital, Stockholm, Sweden.

In both multiple sclerosis (MS) and experimental autoimmune encephalomyelitis, the regulation of the cytokine spectrum and production is likely to have a decisive influence on disease outcome. Studies of cytokines, however, are hampered by the autocrine or paracrine nature of cytokines. Studies of cellular production by messenger RNA detection or cellular secretion are therefore necessary. Collective data suggest that certain cytokines associated with the TH1 phenotype or lymphocytes, such as tumor necrosis factor alpha, lymphotoxin, interleukin-12, and interferon gamma, may promote disease, while cytokines produced by the TH2 subset, such as interleukin-10, may limit disease. In addition, transforming growth factor beta is a putative disease downregulator. Increased knowledge in this field will likely lead to improved therapy for MS patients.


This article has been cited by other articles:


Home page
 J. Exp. Med.Home page
K. Koguchi, D. E. Anderson, L. Yang, K. C. O'Connor, V. K. Kuchroo, and D. A. Hafler
Dysregulated T cell expression of TIM3 in multiple sclerosis
J. Exp. Med., June 12, 2006; 203(6): 1413 - 1418.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G.-X. Zhang, S. Yu, B. Gran, and A. Rostami
Glucosamine Abrogates the Acute Phase of Experimental Autoimmune Encephalomyelitis by Induction of Th2 Response
J. Immunol., December 1, 2005; 175(11): 7202 - 7208.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
I. Nakashima, K. Fujihara, J. Fujimori, K. Narikawa, T. Misu, and Y. Itoyama
Absence of IgG1 response in the cerebrospinal fluid of relapsing neuromyelitis optica
Neurology, January 13, 2004; 62(1): 144 - 146.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G.-X. Zhang, S. Yu, B. Gran, J. Li, I. Siglienti, X. Chen, D. Calida, E. Ventura, M. Kamoun, and A. Rostami
Role of IL-12 Receptor {beta}1 in Regulation of T Cell Response by APC in Experimental Autoimmune Encephalomyelitis
J. Immunol., November 1, 2003; 171(9): 4485 - 4492.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
M. Schluep, G. van Melle, H. Henry, C. Stadler, B. Roth-Wicky, and P. J Magistretti
In vitro cytokine profiles as indicators of relapse activity and clinical course in multiple sclerosis
Multiple Sclerosis, June 1, 1998; 4(3): 198 - 202.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by AAN Enterprises, Inc.